Eli Lilly and Company
NASDAQ: LLYKey stats
Price chart
About Eli Lilly and Company
Pharmaceuticals
Company profile
- IPO date
- Jul 9, 1970
- Website
- www.lilly.com
Healthcare peers
How LLY compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 JNJ Johnson & Johnson | $226.71 | -1.77% | $549.56B | 26.34 |
 ABBV AbbVie Inc. | $210.39 | -0.18% | $371.72B | 87.96 |
 UNH UnitedHealth Group | $393.85 | -1.31% | $358.78B | 30.14 |
 MRK Merck & Co. | $111.38 | -1.79% | $275.09B | 30.79 |
 PFE Pfizer Inc. | $25.33 | -1.63% | $144.17B | 19.57 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
Eli Lilly's strength lies in its innovative pharmaceutical contributions, especially in diabetes and immunology treatments. Drugs like Trulicity and Taltz show strong sales potential, tapping into growing global health concerns. Lilly's research pipeline with drugs focused on solving major health issues like Alzheimer's and cancer reflects a promising future. The company maintains a competitive edge through its substantial R&D investments and strong patent protection. Despite a hefty market cap, the stock enjoys analyst confidence with a strong buy consensus, indicating trust in its future prospects.
Bear case
LLY's high P/E ratio of 43.01 reflects premium investor expectations, which could pose a risk if earnings growth doesn't keep pace. While innovative, Lilly faces stiff competition from big pharma players in key segments like diabetes, where cost pressures and market saturation could limit pricing power. Additionally, the company’s modest dividend yield of 0.6066% may not attract income-focused investors. Regulatory risks and potential setbacks in the development of its new pipelines could also impact performance.
Who should buy LLY
LLY is well-suited for investors with a long-term growth focus who are comfortable with the high valuation multiple and modest dividend yield. Ideal for those interested in the healthcare sector's innovation frontier, willing to accept moderate volatility for potential strong returns from product breakthroughs.
Key risks
- High P/E ratio indicates growth expectations must be met to justify valuation. - Competitive pressures in pharmaceuticals, especially for diabetes and immunology. - Regulatory risks potentially affecting drug approvals and sales. - Dependence on successful advancements in clinical trials for future growth.
Where to buy LLY
Open an account with a broker we've reviewed and start trading Eli Lilly and Company today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent LLY news
Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, while also committing an additional US$4.50 billion to expand its Indiana manufacturing network for obesity and genetic medicines. The combination of durable weight maintenance data for Foundayo and Zepbound and large-scale production expansion underscores how central obesity treatments have become...
Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 10 years. On May 5, Emily Field from Barclays lifted the price target on Eli Lilly and Company (NYSE:LLY) to $1,400 from $1,350 and maintained an Overweight rating following the first-quarter results. In a research note, the analyst […]
The Caitlin Clark Foundation, in partnership with Eli Lilly and Company (NYSE: LLY) and Musco Lighting, has opened three new multi-sport community courts across Indianapolis—creating year-round access to safe, high-quality spaces for youth to play. These latest court openings include two courts at Indianapolis Public Schools—Clarence Farrington and Edison School of the Arts—and a public court at the corner of E. South Street and S. New Jersey Street, that Lilly will provide to the City of Indian
There's a new challenger to the more established players in the weight-loss drug space.
Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks That Will Profit from AI. The company has recently introduced LillyPod, the pharmaceutical industry’s most powerful NVIDIA-powered supercomputer. Embedded with AI, Lillypod is part of a continuous learning system that accelerates drug discovery and development. On May 12, 2026, Eli Lilly and Company […]
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the company announced an additional $4.5 billion investment to expand its U.S. manufacturing capabilities as it prepares for surging demand for its weight-loss medications.
Picture a drug so popular that, even in markets where a cheaper generic competitor had just launched, it still grew by 10%. That's what happened to Eli Lilly's (LLY) Mounjaro in India recently. And it's the kind of detail that makes Morgan Stanley think Wall Street still isn't giving Lilly's ...
Eli Lilly (LLY) stock is back in focus after the company reported a very strong Q1, raised its full year revenue and earnings guidance, and released new obesity trial data on Foundayo and Zepbound. See our latest analysis for Eli Lilly. The recent obesity trial updates, expanded manufacturing plans and steady flow of product news have kept Eli Lilly in the spotlight. A 30 day share price return of 9.13% has helped the stock recover some ground after a year to date decline of 6.82%. The 1 year...
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.